Average cost per year*
Average cost per beneficiary*
Fondaparinux is used to treat serious blood clots in the legs and/or lungs. It is usually used with another "blood thinner" medication (warfarin). If untreated, blood clots can travel to the lungs, heart, or brain, causing serious (possibly fatal) breathing problems, heart attack, or stroke. This drug may also be used to prevent blood clots after certain surgeries with an increased risk of blood clots (such as hip fracture, abdominal, knee/hip replacement). Fondaparinux is known as a "blood thinner" (anticoagulant). It is a drug similar to heparin that works by blocking certain natural substances in the blood that cause clotting. NOTE: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
*Origin of the terms and chart data used within this page: https://data.cms.gov/
Yes, Arixtra is covered by Medicare.
In 2021, the average cost per dose of Arixtra was $185.49.
The average dose of Arixtra received per year is 3,945 units
21 Medicare beneficiaries received Arixtra in 2021, which was a -0.3% from 2020
There were 109 claims made by Medicare beneficiaries, which is a -0.24% from 2020
The average spending amount per claim in 2021 was $3,954.39
The average Medicare spending per beneficiary amount for Arixtra was $20,525.15
Mylan Instituti received $431,028.18
The total amount spent on Arixtra by Medicare is $431,028.18
Short Term Medical Insurance
Limited Fixed Indemnity Plans